{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:35:41Z","timestamp":1792802141643,"version":"4.5.0"},"reference-count":72,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL135008"],"award-info":[{"award-number":["R01HL135008"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL143224"],"award-info":[{"award-number":["R01HL143224"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brigham and Women\u2019s Heart and Vascular Center","award":["Watkins Discovery Award"],"award-info":[{"award-number":["Watkins Discovery Award"]}],"id":[{"id":"https:\/\/ror.org\/04b6nzv94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"American College of Clinical Pharmacy Foundation","award":["New Investigator Award"],"award-info":[{"award-number":["New Investigator Award"]}],"id":[{"id":"https:\/\/ror.org\/02srcnm40","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>After more than a decade of relatively modest advancements, heart failure therapeutic development has accelerated, with the PARADIGM-HF trial and the SHIFT trial demonstrated significant reductions in cardiovascular death and heart failure hospitalization for sacubitril-valsartan and in heart failure hospitalization alone for ivabradine. Several heart failure therapies have since received or stand on the verge of market approval and promise substantive advances in the treatment of chronic heart failure. Some of these improve clinical outcomes, whereas others improve functional or patient-reported outcomes. In light of these rapid advances in the care of adults living with chronic heart failure, in this review we seek to update the general practitioner on novel heart failure therapies. Specifically, we will review recent data on the implementation of sacubitril-valsartan, treatment of functional mitral regurgitation, sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy, agents for transthyretin amyloid cardiomyopathy, treatment of iron deficiency in heart failure, and the use of biomarkers or remote hemodynamic monitoring to guide heart failure therapy.<\/ns4:p>","DOI":"10.12688\/f1000research.20447.1","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T12:05:09Z","timestamp":1576843509000},"page":"2134","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent advances in the treatment of chronic heart failure"],"prefix":"10.12688","volume":"8","author":[{"given":"Leo F","family":"Buckley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1056-4451","authenticated-orcid":false,"given":"Amil M","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"1193-202","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.","volume":"18","author":"M Senni","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"539-548","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.","volume":"380","author":"E Velazquez","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1609-1620","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.","volume":"381","author":"S Solomon","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"763-771","DOI":"10.1016\/j.jchf.2017.06.013","article-title":"Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.","volume":"5","author":"J Hsu","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"993-1004","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"J McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"455-62","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.","volume":"37","author":"S Solomon","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1230-1239","DOI":"10.1002\/ejhf.1149","article-title":"Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.","volume":"20","author":"L Lund","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"776-803","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.","volume":"70","author":"C Yancy","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1231-1248","DOI":"10.1016\/j.jacc.2015.02.009","article-title":"Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations.","volume":"65","author":"A Asgar","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"252-289","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"70","author":"R Nishimura","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1395-406","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous repair or surgery for mitral regurgitation.","volume":"364","author":"T Feldman","year":"2011","journal-title":"N Engl J Med."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"2297-2306","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.","volume":"379","author":"J Obadia","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"2307-2318","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter Mitral-Valve Repair in Patients with Heart Failure.","volume":"379","author":"G Stone","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"584-619","DOI":"10.1016\/j.cardfail.2019.05.007","article-title":"Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America.","volume":"25","author":"S Dunlay","year":"2019","journal-title":"J Card Fail."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"11-26","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.","volume":"13","author":"R DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"1629-1647","DOI":"10.1016\/j.mayocp.2018.07.018","article-title":"Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.","volume":"93","author":"S Carbone","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"2117-28","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"644-657","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"347-357","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.","volume":"380","author":"S Wiviott","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1526-34","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial.","volume":"37","author":"D Fitchett","year":"2016","journal-title":"Eur Heart J."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"458-468","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.","volume":"138","author":"K R\u00e5dholm","year":"2018","journal-title":"Circulation."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"2591-2593","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.","volume":"139","author":"G Figtree","year":"2019","journal-title":"Circulation."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"2528-2536","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.","volume":"139","author":"E Kato","year":"2019","journal-title":"Circulation."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.","volume":"17","author":"F Soga","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","article-title":"Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.","volume":"17","author":"D Matsutani","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1995-2008","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.","volume":"381","author":"J McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"2872-2891","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.","volume":"73","author":"F Ruberg","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"2585-94","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"9629-34","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.","volume":"109","author":"C Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1007-1016","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.","volume":"379","author":"M Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"806-11","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.","volume":"391","author":"A Fire","year":"1998","journal-title":"Nature."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"819-29","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis.","volume":"369","author":"T Coelho","year":"2013","journal-title":"N Engl J Med."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"11-21","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.","volume":"379","author":"D Adams","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"466-472","DOI":"10.1001\/jamacardio.2019.0849","article-title":"Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.","volume":"4","author":"M Minamisawa","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"431-443","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.","volume":"139","author":"S Solomon","year":"2019","journal-title":"Circulation."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"22-31","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.","volume":"379","author":"M Benson","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"285-295","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.","volume":"74","author":"D Judge","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"575-582.e3","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis.","volume":"165","author":"I Klip","year":"2013","journal-title":"Am Heart J."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"1125-1132","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis.","volume":"16","author":"T Yeo","year":"2014","journal-title":"Eur J Heart Fail."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"436-443","DOI":"10.1007\/s00392-016-1073-y","article-title":"Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry.","volume":"106","author":"S von Haehling","year":"2017","journal-title":"Clin Res Cardiol."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"1872-80","DOI":"10.1093\/eurheartj\/ehq158","article-title":"Iron deficiency: an ominous sign in patients with systolic chronic heart failure.","volume":"31","author":"E Jankowska","year":"2010","journal-title":"Eur Heart J."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"806-808","DOI":"10.1002\/ejhf.938","article-title":"Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure.","volume":"20","author":"P Martens","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"547-556","DOI":"10.1002\/jcsm.12282","article-title":"Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure.","volume":"9","author":"M Tkaczyszyn","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"268-75","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study.","volume":"174","author":"C Enjuanes","year":"2014","journal-title":"Int J Cardiol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"522-530","DOI":"10.1002\/ejhf.640","article-title":"Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.","volume":"19","author":"V Melenovsky","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"910-919","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.","volume":"20","author":"M Hoes","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"362-372","DOI":"10.1093\/eurheartj\/ehw333","article-title":"Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.","volume":"38","author":"S Haddad","year":"2017","journal-title":"Eur Heart J."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"786-95","DOI":"10.1002\/ejhf.473","article-title":"Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials.","volume":"18","author":"E Jankowska","year":"2016","journal-title":"Eur J Heart Fail."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1374-1383","DOI":"10.1161\/CIRCULATIONAHA.117.027497","article-title":"Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.","volume":"136","author":"D van Veldhuisen","year":"2017","journal-title":"Circulation."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"2386-2398","DOI":"10.1161\/CIRCULATIONAHA.118.038516","article-title":"Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.","volume":"139","author":"G Charles-Edwards","year":"2019","journal-title":"Circulation."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1958-1966","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.","volume":"317","author":"G Lewis","year":"2017","journal-title":"JAMA."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1981-9","DOI":"10.1182\/blood-2015-05-642223","article-title":"Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women.","volume":"126","author":"D Moretti","year":"2015","journal-title":"Blood."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"e524-e533","DOI":"10.1016\/S2352-3026(17)30182-5","article-title":"Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials.","volume":"4","author":"N Stoffel","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"1559-67","DOI":"10.1093\/eurheartj\/ehu090","article-title":"Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: An individual patient meta-analysis.","volume":"35","author":"R Troughton","year":"2014","journal-title":"Eur Heart J."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"713-720","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.","volume":"318","author":"G Felker","year":"2017","journal-title":"JAMA."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"382-389","DOI":"10.1016\/j.cardfail.2017.02.001","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.","volume":"23","author":"N Davarzani","year":"2017","journal-title":"J Card Fail."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"e240-327","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines.","volume":"128","author":"C Yancy","year":"2013","journal-title":"Circulation."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.rec.2016.11.005","article-title":"2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.","volume":"69","author":"P Ponikowski","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"658-66","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: A randomised controlled trial.","volume":"377","author":"W Abraham","year":"2011","journal-title":"Lancet."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"935-44","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","article-title":"Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction.","volume":"7","author":"P Adamson","year":"2014","journal-title":"Circ Heart Fail."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1509-1517","DOI":"10.1161\/CIRCULATIONAHA.116.026184","article-title":"Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor.","volume":"135","author":"J Heywood","year":"2017","journal-title":"Circulation."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"556-563","DOI":"10.1001\/jamacardio.2019.1384","article-title":"Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort Analysis.","volume":"4","author":"J Abraham","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"333-44","DOI":"10.1016\/j.jchf.2015.11.011","article-title":"Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring.","volume":"4","author":"M Costanzo","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"1875-1886","DOI":"10.1016\/j.jacc.2017.08.010","article-title":"Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.","volume":"70","author":"M Givertz","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"170-176","DOI":"10.1002\/clc.22643","article-title":"Hemodynamic-guided heart-failure management using a wireless implantable sensor: Infrastructure, methods, and results in a community heart failure disease-management program.","volume":"40","author":"R Jermyn","year":"2017","journal-title":"Clin Cardiol."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"304-307","DOI":"10.1016\/j.hrtlng.2018.05.001","article-title":"Burden of nursing activities during hemodynamic monitoring of heart failure patients.","volume":"47","author":"L Buckley","year":"2018","journal-title":"Heart Lung."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"4918757","DOI":"10.1155\/2018\/4918757","article-title":"CardioMEMS in a Busy Cardiology Practice: Less than Optimal Implementation of a Valuable Tool to Reduce Heart Failure Readmissions.","volume":"2018","author":"R Singh","year":"2018","journal-title":"Cardiol Res Pract."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"368-75","DOI":"10.1016\/j.jchf.2015.12.015","article-title":"Cost-Effectiveness of Implantable Pulmonary Artery Pressure Monitoring in Chronic Heart Failure.","volume":"4","author":"A Sandhu","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"1551-1552","DOI":"10.1001\/jamainternmed.2016.5467","article-title":"CardioMEMS HF for the Management of Heart Failure-Effectiveness and Value.","volume":"176","author":"D Ollendorf","year":"2016","journal-title":"JAMA Intern Med."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"194-201","DOI":"10.1002\/ehf2.12392","article-title":"Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study.","volume":"6","author":"J Veenis","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"138-145","DOI":"10.1002\/ehf2.12373","article-title":"Changes in pulmonary artery pressure before and after left ventricular assist device implantation in patients utilizing remote haemodynamic monitoring.","volume":"6","author":"A Kilic","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"169-173","DOI":"10.1016\/j.ijcard.2018.03.093","article-title":"Effect of sacubitril\/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction.","volume":"271","author":"Z Khan","year":"2018","journal-title":"Int J Cardiol."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T04:40:14Z","timestamp":1577162414000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":72,"URL":"https:\/\/doi.org\/10.12688\/f1000research.20447.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.22478.r57913","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22478.r57912","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.22478.r57914","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.22478.r57912, Ferdinando Iellamo, Research Institute San Raffaele Pisana, Rome, Italy, 24 Dec 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1#referee-response-57912","order":0,"name":"referee-response-57912","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22478.r57913, Chim C Lang, Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK, 24 Dec 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1#referee-response-57913","order":1,"name":"referee-response-57913","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.22478.r57914, Jawahar L Mehta, Division of Cardiology, Central Arkansas Veterans Healthcare System and the University of Arkansas for Medical Sciences, Arkansas, USA, 24 Dec 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-2134\/v1#referee-response-57914","order":2,"name":"referee-response-57914","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The work for this review was supported by an American College of Clinical Pharmacy Foundation New Investigator Award (LFB); National Heart, Lung, and Blood Institute grants R01HL135008 and R01HL143224 (AMS); and a Watkins Discovery Award from the Brigham and Women\u2019s Heart and Vascular Center (AMS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}